Abstract: Methods for providing post-operative pain control or relief, without a medically significant degree of numbness, to a patient are disclosed. Methods include, for example, administering bicarbonate and a calcium salt to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, in an area previously administered or containing a regional or local anesthetic, in an amount sufficient to provide the patient with pain control or relief, without a medically significant degree of numbness, for a period of time after the surgical or dental procedure.

Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects.

Abstract: A method of making a sacrificial coating composition is disclosed. The method comprises emulsifying an oil with surfactant and water to form an oil-in-water emulsion; and combining ingredients comprising (i) at least one polymer, (ii) at least one hygroscopic material, (iii) the oil-in water emulsion and (iv) water to produce the sacrificial coating composition. The at least one polymer is selected from the group consisting of a hydrophilic polymer, a latex comprising polymer particles dispersed in a continuous liquid phase, or mixtures thereof.

Abstract: A coating composition for an image transfer member in an aqueous ink imaging system. The coating composition includes at least one hydrophilic polymer, at least one hygroscopic material, at least one oil-in-water emulsion and at least one surfactant.

Abstract: An absorbent article is provided with a liquid-permeable top sheet, a liquid-impermeable back sheet and an absorbent body between the top sheet and the back sheet. The top sheet has a non-woven fabric having multiple convex portions and multiple concave portions. The individual convex portions and concave portions contain a blood lubricity-imparting agent that has a kinetic viscosity of 0.01-80 mm2/s at 40° C., a water retention rate of 0.01-4.0 mass % and a weight-average molecular weight of less than 1,000. The amount of the blood lubricity-imparting agent at the top of the convex portions is larger than in the parts other than the top of the convex portions. The amount of the blood lubricity-imparting agent at the bottom of the concave portions is larger than in the parts other than the bottom of the concave portions.

Abstract: The invention relates to formulations that comprise non-irritating non-toxic compounds that may be applied to the skin for generally improvement of health and beauty. The formulations include core ingredients of minerals, oils, and emulsifiers. Additional ingredients may be added to provide a variety of formulations for skin hydration, softening, soothing, deodorizing, and cosmetic application. The formulations may be use as a carrier for cosmetics, fragrances, or therapeutic agents.

Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.

Abstract: The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.

Abstract: This invention provides an emulsifiable concentrate composition, containing a component (A) which is at least one selected from the group consisting of alkanol having 6 to 20 carbon atoms, alkenol having 6 to 20 carbons, polyoxyethylene alkyl ester, polyoxyethylene alkyl diester, polyoxyethylene alkenyl ester, polyoxyethylene dialkenyl ester, polyoxyethylene•polyoxypropylene•block copolymer and a silicon-based surfactant, a component (B) which is at least one polyoxyalkylene aryl phenyl ether, and a component (C) which is an aromatic hydrocarbon-based nonpolar solvent, wherein the emulsifiable concentrate composition contains neither anionic surfactant nor cationic surfactant, and an agrochemical emulsifiable concentrate composition using the emulsifiable concentrate composition.

Abstract: This invention relates to a dental appliance cleanser which is a metastable emulsion comprising about 50-99% w/w of an aqueous phase, about 1-50% w/w of a water immiscible oily phase, the oily phase having a combination of a one or more immiscible oils and one or more flavor oils. The dental appliance cleanser is applied to the dental appliance, outside the wearer's mouth, in the form of an aerated foam.

Abstract: A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.

Abstract: An apparatus is provided comprising one or more matrices contained within a shell, wherein the one or more matrices comprise between 1-99 wt % of a water-insoluble host material and between 1-99 wt % of a guest substrate, wherein the guest substrate comprises between 1-100 wt % of one or more disinfectant compounds or one or more beneficial compounds; and wherein the shell comprises a water-insoluble shell polymer, and one or more apertures. The host material may be a polymer. The apparatus is used for treating an aqueous medium with one or more disinfectant compounds or one or more beneficial compounds.

Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection.

Abstract: The invention relates to a biodegradable fleece containing (i) at least one polymer for inducing primary haemostasis, (ii) at least one non-proteinogenic, low-molecular, water-soluble activator of secondary haemostasis, and (iii) at least one non-proteinogenic, low-molecular, water-soluble inhibitor of fibrinolysis. The invention also relates to a method for producing a biodegradable fleece, in which (i) a fluidised fiber raw material, and additives if applicable, is placed in a container, (ii) the container is made to rotate, (iii) the fluidised fiber raw material is dispensed from the container by means of centrifugal forces, whereby fibers or filaments are formed, and (iv) a biodegradable fleece is produced from the fibers or filaments. The invention also relates to the use of said biodegradable fleece as a local haemostatic agent.

Abstract: A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.

Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”). The invention of intratumoral injection with the “medicinal ion bomb” can be used as the first-line treatment in treating cancer and tumor in nine human organs (carcinoma and tumor of the skin and subcutaneous tissue, breast, prostate, thyroid, lung, liver, genital organ, brain and pancreas) and certain other benign diseases (skin and subcutaneous neoplasm, breast fibrocystic change, benign prostatic hyperplasia and thyroid nodules).

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The present disclosure provides method of inducing secretion of beta-endorphin in a skin region of a subject, the method comprises topically applying a composition comprising at least 0.5% Dead Sea Water onto a skin region of a subject. The disclosure further provides a method of modifying at least one condition of a skin region of a subject, the method comprises topically applying a composition comprising at least 0.5% Dead Sea Water onto the skin region of the subject, wherein the at least one skin condition is selected from the group consisting of mechanical and physiological skin condition and wherein the modifying of the at least one skin condition is associated with induction of skin beta-endorphin secretion in the skin region.

Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

Abstract: Particles and related methods are disclosed.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The precursor of an acidic dialysis concentrate is characterized in that two separately provided partial concentrates are formed from the constituents of the acidic dialysis concentrate, wherein only the one partial concentrate contains glucose, preferably glucose monohydrate, while the other partial concentrate comprises other constituents needed for the acidic dialysis concentrate.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.

Abstract: The present disclosure is directed to dispersions of a Dead Sea material in oil, the Dead Sea material is present in the dispersions in the form of solid nanoparticles. Further disclosed are formulations comprising the dispersions, method of treating and/or preventing diseases or disorders of the skin comprising topical application of the dispersions or formulations thereof onto a skin of a subject, method of inducing a heat sensation on the skin of a subject by topically applying the dispersions or formulations thereof onto a skin of a subject and methods of preparing the dispersions.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention said glucose and said at least one magnesium salt, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.

Abstract: Cements containing certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as but not limited to calcium phosphate have been found to have improved properties and form a macromolecular network in the presence of a bioactive glass material that contain silicates, phosphates, and calcium salts which can be involved in the formation of bonding sites.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The present invention relates to improved compositions for controlling marine pest anemones, to methods of application of same, and to kits for the convenient dispensing of such compositions.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present invention relates to a container comprising at least a dry concentrate, wherein the dry concentrate is designed such that it forms at least one acid liquid concentrate, or a part of an acid liquid concentrate, which is suitable for manufacturing at least on dialysis solution, on its dissolving in a liquid, preferably in water.

Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.

Abstract: Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a ?L-crystallin electrostatic interaction inhibitor. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins, particularly ?L-crystallin. It has been found that the aggregation of ?L-crystallin is an electrostatic phenomenon and that electrostatic interaction inhibitors can be employed to prevent the formation of ?L-crystallin aggregates as well as to deaggregate already formed aggregates.

Abstract: The subject matter of the present invention is a multichamber container and a method for preparing medical fluids composed of concentrates which make a contribution toward the electrical conductivity of the solution and are additionally prepared from concentrates which do not make a contribution toward the electrical conductivity of the solution. The inventive multichamber container is characterized in that it is constructed by dividing the solution components into multiple chambers, so that following the dissolving due to breaking open of the first chamber border of a solution component, which makes a contribution toward the electrical conductivity of the medicinal solution, another chamber border of another solution component which does not make any contribution toward the electrical conductivity of the solution is broken open.

Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

Abstract: A beverage for minimizing or reducing jet lag symptoms preferably includes vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin D, zinc, calcium, iodine, magnesium, manganese, ginseng, ginkgo biloba, grape seed extract, Echinacea extract and water. A method for minimizing or reducing jet lag symptoms including ingestion of the beverage by a traveler, one hour prior to a flight, and/or during the flight, and/or after a flight.

Abstract: The present invention realtes to compositions and methods to improve the microenvironments in and around the wound in an effort to enhance healing. Specifically, the present invention comprises application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or cinnamon extracts including but not limited to MHCP. The media is applied to the wound to stimulate the viable cells in the wound bed and the adjacent cells in the periphery of the wound to proliferate and grow into the wound in order to achieve wound closure.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.

Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.

Abstract: Cell-8 Solution is an intravenous solution introduced into the veins of the patient. Cell-8 Solution provides the cells of the body with highly absorbed minerals as well as new RNA information which changes the relationship of the body to the cancer in question. Treatment with Cell-8 Solution will prevent the body from accepting the existence of cancer cells so that cancer cell replication will no longer occur. Although intravenous Cell-8 Solution is superior, other applications include nebulized, transdermal and oral.

Abstract: The present invention comprises an all-natural composition of matter and methods of delivering nutrients, medicines, pain relievers, antioxidants, antidotes, antibiotics and various active ingredients and supplements directly to the affected area of the body. The all-natural carrier composition consists essentially of the combination of a natural oil, water, salt(s), natural emulsifier, natural sugar(s), plant extracts, natural acid(s), starch and natural flavor(s). The active substances that are mixed with the all-natural carrier composition, include, but are not limited to, drugs, vitamins, minerals, antibiotics anti fungal agents, antioxidants, diuretics, allergy medicines, anti-inflammatory agents, muscle relaxers, pain reducers, diabetic drugs, neuropathy drugs, chemotherapy agents, arthritis drugs, lotions for eczema, shingles, psoriasis, skin rash; herbal medicines, erectile dysfunction drugs, hormones, cholesterol drugs, essential fatty acids, and the like.